Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Molecular imaging for monitoring treatment response in breast cancer patients.

Bensch F, van Kruchten M, Lamberts LE, Schröder CP, Hospers GA, Brouwers AH, van Vugt MA, de Vries EG.

Eur J Pharmacol. 2013 Oct 5;717(1-3):2-11. doi: 10.1016/j.ejphar.2013.01.079. Epub 2013 Mar 30. Review.

PMID:
23545359
2.

Novel methods and tracers for breast cancer imaging.

Linden HM, Dehdashti F.

Semin Nucl Med. 2013 Jul;43(4):324-9. doi: 10.1053/j.semnuclmed.2013.02.003. Review.

PMID:
23725994
3.

Molecular pathways and molecular imaging in breast cancer: an update.

Cervino AR, Burei M, Mansi L, Evangelista L.

Nucl Med Biol. 2013 Jul;40(5):581-91. doi: 10.1016/j.nucmedbio.2013.03.002. Epub 2013 Apr 17. Review.

PMID:
23602603
4.

Molecular imaging in ovarian cancer.

Reyners AK, Broekman KE, Glaudemans AW, Brouwers AH, Arts HJ, van der Zee AG, de Vries EG, Jalving M.

Ann Oncol. 2016 Apr;27 Suppl 1:i23-i29. doi: 10.1093/annonc/mdw091.

PMID:
27141066
5.

Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.

Gaeta CM, Vercher-Conejero JL, Sher AC, Kohan A, Rubbert C, Avril N.

Q J Nucl Med Mol Imaging. 2013 Dec;57(4):352-66. Review.

6.

(18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go.

Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czernin J.

Q J Nucl Med Mol Imaging. 2011 Dec;55(6):620-32. Review.

PMID:
22231582
7.

Imaging cellular receptors in breast cancers: an overview.

Sekar TV, Dhanabalan A, Paulmurugan R.

Curr Pharm Biotechnol. 2011 Apr;12(4):508-27. Review.

PMID:
21342102
8.

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S.

J Nucl Med. 2013 Nov;54(11):1862-8. doi: 10.2967/jnumed.112.119271. Epub 2013 Oct 3.

9.

Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.

Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F.

J Nucl Med. 2013 Dec;54(12):2062-9. doi: 10.2967/jnumed.113.119909. Epub 2013 Oct 17.

10.

18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.

McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM.

J Nucl Med. 2009 Nov;50(11):1848-56. doi: 10.2967/jnumed.109.067231. Epub 2009 Oct 16.

11.

Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.

Hoffmann J, Sommer A.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):191-200. Epub 2005 Jan 28.

PMID:
15860262
12.

RECIST revisited: a review of validation studies on tumour assessment.

Therasse P, Eisenhauer EA, Verweij J.

Eur J Cancer. 2006 May;42(8):1031-9. Epub 2006 Apr 17. Review.

PMID:
16616487
13.

Breast cancer therapy: the role of PET-CT in decision making.

Pons F, Duch J, Fuster D.

Q J Nucl Med Mol Imaging. 2009 Apr;53(2):210-23. Review.

14.

Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer.

Tchou J, Sonnad SS, Bergey MR, Basu S, Tomaszewski J, Alavi A, Schnall M.

Mol Imaging Biol. 2010 Dec;12(6):657-62. doi: 10.1007/s11307-009-0294-0. Epub 2009 Dec 12.

PMID:
20012701
15.

Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.

Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF.

J Vasc Interv Radiol. 2007 Aug;18(8):957-63.

PMID:
17675611
16.

Molecular targeting of breast cancer: imaging and therapy.

Padmanabhan P, Goggi J, Bejot R, Bhakoo KK.

Curr Pharm Biotechnol. 2011 Apr;12(4):528-38. Review.

PMID:
21342104
17.

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J.

J Nucl Med. 2010 Jun;51(6):892-7. doi: 10.2967/jnumed.109.073239. Epub 2010 May 19.

19.

First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.

Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH, Buerger H.

J Pathol. 2005 Jul;206(3):366-76.

PMID:
15892165
20.

Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.

Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, Langström B, Bergström M.

Nucl Med Biol. 2009 Apr;36(3):335-42. doi: 10.1016/j.nucmedbio.2008.12.009.

PMID:
19324279

Supplemental Content

Support Center